MiRXES
MiRXES is a Singapore-headquartered biotechnology company.
Mirxes reports $95.4m net loss ahead of IPO
Mirxes reports $95.4m net loss ahead of IPO
Costs of R&D and administrative activities widened last year’s losses.
Read Here
Advertise
Sign Up
Commentary
2026 biotech playbook: Hong Kong at the centre of China’s globalisation
Navigating Hong Kong’s regulatory landscape: a challenging and rewarding endeavour
Wellness craze: Emerging growth for commercial space